Icon

SIMBRINZA (nda204251)- (0.2%;1%)

BRIMONIDINE TARTRATE; BRINZOLAMIDE ALCON LABS INC
0.2%;1%
Yes Yes
2030-Oct-30 Expired
None None
None No
SIMBRINZA™ is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
0 1 0
Total Other Developers 11
Drugs with Suitability No
0.2%;1% ** ** Up - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.